Concepts (114)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pneumothorax | 2 | 2019 | 79 | 0.660 |
Why?
|
| Electric Impedance | 2 | 2019 | 72 | 0.580 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 3 | 2019 | 41 | 0.330 |
Why?
|
| Pleura | 2 | 2019 | 27 | 0.290 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2019 | 88 | 0.280 |
Why?
|
| Abortion, Induced | 1 | 2024 | 89 | 0.190 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2022 | 78 | 0.180 |
Why?
|
| Benzamides | 2 | 2019 | 125 | 0.180 |
Why?
|
| Obstetrics | 1 | 2024 | 241 | 0.170 |
Why?
|
| Hysterectomy | 1 | 2022 | 199 | 0.170 |
Why?
|
| Pyridines | 2 | 2019 | 260 | 0.160 |
Why?
|
| Fellowships and Scholarships | 1 | 2024 | 324 | 0.160 |
Why?
|
| Placenta Accreta | 1 | 2022 | 175 | 0.160 |
Why?
|
| Transducers | 1 | 2019 | 22 | 0.150 |
Why?
|
| Cesarean Section | 1 | 2022 | 426 | 0.150 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2019 | 148 | 0.150 |
Why?
|
| Mental Health | 1 | 2022 | 370 | 0.150 |
Why?
|
| Paired Box Transcription Factors | 1 | 2018 | 73 | 0.140 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2019 | 50 | 0.140 |
Why?
|
| Tidal Volume | 1 | 2018 | 42 | 0.140 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 702 | 0.140 |
Why?
|
| Fluoroscopy | 1 | 2018 | 101 | 0.140 |
Why?
|
| Histone Deacetylases | 1 | 2018 | 130 | 0.130 |
Why?
|
| DNA Helicases | 1 | 2018 | 237 | 0.130 |
Why?
|
| Computational Biology | 2 | 2019 | 868 | 0.130 |
Why?
|
| Models, Statistical | 1 | 2019 | 482 | 0.120 |
Why?
|
| Receptors, Somatomedin | 1 | 2016 | 21 | 0.120 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2018 | 243 | 0.120 |
Why?
|
| Influenza, Human | 1 | 2022 | 700 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 1170 | 0.120 |
Why?
|
| Precision Medicine | 1 | 2019 | 386 | 0.120 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 1115 | 0.110 |
Why?
|
| Respiration, Artificial | 1 | 2018 | 505 | 0.110 |
Why?
|
| Meningeal Neoplasms | 1 | 2016 | 220 | 0.100 |
Why?
|
| Depression | 1 | 2022 | 1321 | 0.100 |
Why?
|
| Cerebellar Neoplasms | 1 | 2016 | 328 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 1230 | 0.090 |
Why?
|
| Medulloblastoma | 1 | 2016 | 390 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2018 | 896 | 0.090 |
Why?
|
| Cell Line, Tumor | 4 | 2019 | 3727 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2018 | 2454 | 0.070 |
Why?
|
| Mice, Inbred NOD | 2 | 2019 | 301 | 0.070 |
Why?
|
| Vincristine | 2 | 2019 | 190 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2019 | 113 | 0.070 |
Why?
|
| Animals | 5 | 2019 | 33981 | 0.070 |
Why?
|
| Pregnancy | 3 | 2024 | 7402 | 0.060 |
Why?
|
| 1,2-Dimethylhydrazine | 1 | 2022 | 6 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2022 | 3393 | 0.050 |
Why?
|
| Gynecology | 1 | 2024 | 127 | 0.050 |
Why?
|
| Placenta Previa | 1 | 2022 | 65 | 0.050 |
Why?
|
| Female | 7 | 2024 | 70550 | 0.040 |
Why?
|
| Child Health | 1 | 2022 | 67 | 0.040 |
Why?
|
| Social Determinants of Health | 1 | 2022 | 165 | 0.040 |
Why?
|
| Chest Tubes | 1 | 2019 | 38 | 0.040 |
Why?
|
| Suction | 1 | 2019 | 50 | 0.040 |
Why?
|
| Histone Deacetylase 1 | 1 | 2019 | 20 | 0.040 |
Why?
|
| Sus scrofa | 1 | 2019 | 112 | 0.040 |
Why?
|
| PAX3 Transcription Factor | 1 | 2018 | 26 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2019 | 236 | 0.040 |
Why?
|
| Humans | 8 | 2024 | 130854 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2019 | 100 | 0.040 |
Why?
|
| Heterografts | 1 | 2019 | 193 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 4682 | 0.040 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2018 | 99 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2019 | 239 | 0.040 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2018 | 69 | 0.030 |
Why?
|
| Dogs | 1 | 2019 | 616 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2018 | 360 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2018 | 231 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2019 | 589 | 0.030 |
Why?
|
| Cellular Reprogramming | 1 | 2019 | 128 | 0.030 |
Why?
|
| Equipment Design | 1 | 2019 | 542 | 0.030 |
Why?
|
| Mice | 3 | 2019 | 18267 | 0.030 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 1797 | 0.030 |
Why?
|
| Infant, Premature | 1 | 2022 | 853 | 0.030 |
Why?
|
| Vaccination | 1 | 2022 | 1042 | 0.030 |
Why?
|
| Adolescent | 3 | 2022 | 20818 | 0.030 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2016 | 37 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 1082 | 0.030 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2016 | 43 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2016 | 85 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2016 | 49 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2019 | 318 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 997 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2016 | 94 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2016 | 134 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 418 | 0.030 |
Why?
|
| Anxiety | 1 | 2022 | 1004 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2016 | 308 | 0.030 |
Why?
|
| Child | 3 | 2022 | 26215 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 701 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2016 | 323 | 0.030 |
Why?
|
| Texas | 1 | 2022 | 3635 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 2303 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 4017 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2024 | 1216 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 813 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 380 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 765 | 0.020 |
Why?
|
| Cell Movement | 1 | 2016 | 872 | 0.020 |
Why?
|
| Gene Expression | 1 | 2016 | 1492 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1317 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2022 | 6448 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1833 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2019 | 1935 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 2031 | 0.020 |
Why?
|
| Male | 3 | 2024 | 64763 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2022 | 8509 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 6217 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 2483 | 0.020 |
Why?
|
| United States | 1 | 2024 | 11865 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 1613 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2019 | 15016 | 0.010 |
Why?
|
| Adult | 1 | 2024 | 31238 | 0.010 |
Why?
|